The KANK1 Knockout SK-HEP-1 Polyclonal Cells consist of a CRISPR/Cas9-mediated polyclonal knockout cell population originating from the SK-HEP-1 human liver sinusoidal endothelial cell line. By introducing targeted disruptions in the KANK1 gene, this product generates a heterogeneous pool of cells that collectively lack functional KANK1 protein, establishing a versatile loss-of-function model. The polyclonal format minimizes clone-specific artifacts and is well-suited for population-based biochemical and cell biological assays investigating KANK1??s role in adhesion, migration, and cytoskeletal organization.
SK-HEP-1 cells were derived from the ascitic fluid of a patient diagnosed with liver adenocarcinoma and were initially characterized as endothelial-like, making them a standard in vitro model for liver sinusoidal endothelial cells (LSECs). This cell line retains key LSEC features, including barrier function, endocytosis, and immune surveillance properties, and is routinely employed in studies of hepatic sinusoidal biology and hepatocellular carcinoma (HCC). Because LSECs constitute the hepatic vascular niche and contribute to the tumor microenvironment, SK-HEP-1 cells are particularly valuable for investigating mechanisms of HCC progression and metastasis.
KANK1 functions as a critical adaptor protein that links integrin-based adhesions to the actin cytoskeleton. It interacts with talin1 and talin2 at integrin-rich sites, stabilizing focal adhesions and inhibiting RhoA-ROCK signaling. KANK1 activity is modulated by integrin engagement, TGF-beta, and matrix stiffness. Its loss disrupts talin-integrin-liprin-beta1 complexes, leading to RhoA activation, increased FAK/paxillin phosphorylation, and enhanced actomyosin contractility, which promotes cell migration and invasion. These molecular events underscore KANK1??s tumor-suppressive role in hepatocellular carcinoma.
The SK-HEP-1 cell background offers a physiologically relevant platform to dissect KANK1-dependent processes in liver endothelial cells. LSECs form a selective barrier between the bloodstream and hepatocytes, and their dysfunction can promote liver disease and tumor metastasis. By ablating KANK1 in this cell type, researchers can examine how loss of adhesion stability and elevated RhoA-ROCK activity impact endothelial barrier integrity, endocytosis, and immune surveillance. This model is particularly powerful for studying the endothelial contribution to the pre-metastatic niche in HCC, including altered secretion of cytokines, increased vascular permeability, and facilitation of tumor cell transendothelial migration.
This polyclonal knockout product supports applications in cancer biology, metastasis research, and cytoskeletal regulation. Assays include western blotting for KANK1 and downstream targets (FAK, paxillin), immunofluorescence staining of focal adhesion proteins, migration assays (wound healing, transwell), RhoA activation pull-downs, co-immunoprecipitation of talin-integrin complexes, and adhesion assays. These techniques allow detailed dissection of KANK1 signaling in liver endothelial biology and HCC metastasis. For further information, contact Ascent Research.
